Trial Profile
Predictive marker of response to Trasutuzumab/Pertuzumab/Taxane therapy by microRNA in HER2 positive Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Taxanes (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 23 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies